190 related articles for article (PubMed ID: 27603567)
1. Noncoding RNAs and Duchenne muscular dystrophy.
Perry MM; Muntoni F
Epigenomics; 2016 Nov; 8(11):1527-1537. PubMed ID: 27603567
[TBL] [Abstract][Full Text] [Related]
2. Noncoding RNAs in Duchenne and Becker muscular dystrophies: role in pathogenesis and future prognostic and therapeutic perspectives.
Brusa R; Magri F; Bresolin N; Comi GP; Corti S
Cell Mol Life Sci; 2020 Nov; 77(21):4299-4313. PubMed ID: 32350552
[TBL] [Abstract][Full Text] [Related]
3. Identification in GRMD dog muscle of critical miRNAs involved in pathophysiology and effects associated with MuStem cell transplantation.
Robriquet F; Babarit C; Larcher T; Dubreil L; Ledevin M; Goubin H; Rouger K; Guével L
BMC Musculoskelet Disord; 2016 May; 17():209. PubMed ID: 27170302
[TBL] [Abstract][Full Text] [Related]
4. The golden retriever model of Duchenne muscular dystrophy.
Kornegay JN
Skelet Muscle; 2017 May; 7(1):9. PubMed ID: 28526070
[TBL] [Abstract][Full Text] [Related]
5. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
6. Expression profiling of disease progression in canine model of Duchenne muscular dystrophy.
Brinkmeyer-Langford C; Chu C; Balog-Alvarez C; Yu X; Cai JJ; Nabity M; Kornegay JN
PLoS One; 2018; 13(3):e0194485. PubMed ID: 29554127
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy.
Brinkmeyer-Langford C; Balog-Alvarez C; Cai JJ; Davis BW; Kornegay JN
BMC Genomics; 2016 Aug; 17(1):665. PubMed ID: 27549615
[TBL] [Abstract][Full Text] [Related]
8. Biomarker Potential of Extracellular miRNAs in Duchenne Muscular Dystrophy.
Coenen-Stass AML; Wood MJA; Roberts TC
Trends Mol Med; 2017 Nov; 23(11):989-1001. PubMed ID: 28988850
[TBL] [Abstract][Full Text] [Related]
9. What do animal models have to tell us regarding Duchenne muscular dystrophy?
Wells DJ; Wells KE
Acta Myol; 2005 Dec; 24(3):172-80. PubMed ID: 16629050
[TBL] [Abstract][Full Text] [Related]
10. Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients.
Jeanson-Leh L; Lameth J; Krimi S; Buisset J; Amor F; Le Guiner C; Barthélémy I; Servais L; Blot S; Voit T; Israeli D
Am J Pathol; 2014 Nov; 184(11):2885-98. PubMed ID: 25194663
[TBL] [Abstract][Full Text] [Related]
11. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
Banks GB; Chamberlain JS
Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle fibrosis in the mdx/utrn+/- mouse validates its suitability as a murine model of Duchenne muscular dystrophy.
Gutpell KM; Hrinivich WT; Hoffman LM
PLoS One; 2015; 10(1):e0117306. PubMed ID: 25607927
[TBL] [Abstract][Full Text] [Related]
13. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the expression profile of circRNAs and their predicted protein-coding ability in the muscle of mdx mice.
Song Z; Liu Y; Fang X; Xie M; Ma Z; Zhong Z; Feng X; Zhang W
Funct Integr Genomics; 2020 May; 20(3):397-407. PubMed ID: 31736012
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 4 inhibitor and phosphodiesterase 5 inhibitor combination therapy has antifibrotic and anti-inflammatory effects in mdx mice with Duchenne muscular dystrophy.
Nio Y; Tanaka M; Hirozane Y; Muraki Y; Okawara M; Hazama M; Matsuo T
FASEB J; 2017 Dec; 31(12):5307-5320. PubMed ID: 28798156
[TBL] [Abstract][Full Text] [Related]
16. Common micro-RNA signature in skeletal muscle damage and regeneration induced by Duchenne muscular dystrophy and acute ischemia.
Greco S; De Simone M; Colussi C; Zaccagnini G; Fasanaro P; Pescatori M; Cardani R; Perbellini R; Isaia E; Sale P; Meola G; Capogrossi MC; Gaetano C; Martelli F
FASEB J; 2009 Oct; 23(10):3335-46. PubMed ID: 19528256
[TBL] [Abstract][Full Text] [Related]
17. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
[TBL] [Abstract][Full Text] [Related]
18. Utrophin upregulation in Duchenne muscular dystrophy.
Hirst RC; McCullagh KJ; Davies KE
Acta Myol; 2005 Dec; 24(3):209-16. PubMed ID: 16629055
[TBL] [Abstract][Full Text] [Related]
19. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.
van der Pijl EM; van Putten M; Niks EH; Verschuuren JJ; Aartsma-Rus A; Plomp JJ
Eur J Neurosci; 2016 Jun; 43(12):1623-35. PubMed ID: 27037492
[TBL] [Abstract][Full Text] [Related]
20. The first exon duplication mouse model of Duchenne muscular dystrophy: A tool for therapeutic development.
Vulin A; Wein N; Simmons TR; Rutherford AM; Findlay AR; Yurkoski JA; Kaminoh Y; Flanigan KM
Neuromuscul Disord; 2015 Nov; 25(11):827-34. PubMed ID: 26365037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
